About
Unigen^TM
Pipeline
Clinical Trials
Investors
Publications

Quarterly Results and Annual Reports

Overview

Select a year:

Proxy Statement

Headquarters

Compugen Ltd.

Azrieli Center
26 Harokmim St., Bldg D
Holon 5885849, Israel

Investor Contact

Yvonne Naughton, PhD, CIR
Vice President and
Head of Investor Relations and Corporate Communications
Cambridge,
United Kingdom

Telephone: +16282410071
Email: yvonnen@cgen.com

Investor Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Compugen, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Compugen to send you the requested Investor Email Alert updates.

* Required

Your Email *

Mailing Lists *

Press Releases
Events
End of Day Stock Quote

Email Alert Sign Up Confirmation

About

Unigen^TM
- Overview

Pipeline

Clinical trials
- COM701/COM902/Pembrolizumab Triple Combination
- Rilvegostomig

Publications
Investors
Careers & Culture
Contact

Privacy Policy
Terms of Use
Accessibility Statement

Toggle toolbar

Accessibility Tools

Increase Text
Decrease Text
Grayscale
High Contrast
Negative Contrast
Light Background
Links Underline
Readable Font
Reset